Germany's Merck Swaps CAR-T Rights For Equity In Intrexon, Focusing Its R&D
Executive Summary
Merck KGaA has rejigged a 2015 drug development deal with NASDAQ-listed Intrexon, swapping rights to potential CAR-T therapies for stock in the biology specialist.